Products - Diabetes | Topic

Showing 32 products

Date | Sort by Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Ranibizumab for treating diabetic retinopathy (terminated appraisal) (TA637)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 June 2020
Sotagliflozin with insulin for treating type 1 diabetes (TA622)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 February 2020
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (TA613)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 November 2019
Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 June 2019
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 March 2019
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
23 November 2016
Published:
26 June 2013
Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 November 2016
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 May 2016
Aflibercept for treating diabetic macular oedema (TA346)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 July 2015
Dexamethasone intravitreal implant for treating diabetic macular oedema (TA349)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 July 2015
Empagliflozin in combination therapy for treating type 2 diabetes (TA336)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 March 2015
Canagliflozin in combination therapy for treating type 2 diabetes (TA315)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 June 2014
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (TA301)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 November 2013
Ranibizumab for treating diabetic macular oedema (TA274)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 February 2013
Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 July 2008
Finerenone for treating chronic kidney disease in people with type 2 diabetes [ID3773]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
10 August 2022
Dexamethasone intravitreal implant for treating diabetic macular oedema in people without a pseudophakic lens [ID3951]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
14 September 2022
Brolucizumab for treating diabetic macular oedema [ID3902]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
16 November 2022
Diabetic retinopathy - ruboxistaurin [ID382]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Macular oedema (diabetic) - pegaptanib sodium [ID452]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Diabetes - buccal insulin [ID311]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Semaglutide for treating type 2 diabetes (ID1450)
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dulaglutide for treating type 2 diabetes [ID1451]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sotagliflozin for treating type 2 diabetes [ID1657]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Faricimab for treating diabetic macular oedema [ID3899]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tirzepatide for treating type 2 diabetes ID3938
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Teplizumab for delaying the onset of type 1 diabetes in people 8 years and over at risk of developing the condition TS ID 10753
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Diabetes Products

Filter

Product type

Guidance programme
1 selected

Status

New and updated

Showing 32 products

Ranibizumab for treating diabetic retinopathy (terminated appraisal) (TA637)

Sotagliflozin with insulin for treating type 1 diabetes (TA622)

Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (TA613)

Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)

Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)

Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)

Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)

Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)

Aflibercept for treating diabetic macular oedema (TA346)

Dexamethasone intravitreal implant for treating diabetic macular oedema (TA349)

Empagliflozin in combination therapy for treating type 2 diabetes (TA336)

Canagliflozin in combination therapy for treating type 2 diabetes (TA315)

Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (TA301)

Ranibizumab for treating diabetic macular oedema (TA274)

Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)

Finerenone for treating chronic kidney disease in people with type 2 diabetes [ID3773]

Dexamethasone intravitreal implant for treating diabetic macular oedema in people without a pseudophakic lens [ID3951]

Brolucizumab for treating diabetic macular oedema [ID3902]

Diabetic retinopathy - ruboxistaurin [ID382]

Macular oedema (diabetic) - pegaptanib sodium [ID452]

Diabetes - buccal insulin [ID311]

Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]

Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275

Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]

Semaglutide for treating type 2 diabetes (ID1450)

Dulaglutide for treating type 2 diabetes [ID1451]

Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]

Sotagliflozin for treating type 2 diabetes [ID1657]

Faricimab for treating diabetic macular oedema [ID3899]

Tirzepatide for treating type 2 diabetes ID3938

Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes

Teplizumab for delaying the onset of type 1 diabetes in people 8 years and over at risk of developing the condition TS ID 10753

Diabetes Products

Filter

Product type

Guidance programme1 selected

Status

New and updated

Showing 32 products

Guidance programme
1 selected